Targeting of Wnt/β-Catenin by anthelmintic drug pyrvinium enhances sensitivity of ovarian cancer cells to chemotherapy

Medical Science Monitor

Volumn 23, Issue , 2017, Pages 266-275

  Zhang, Chongyuan ^a   Zhang, Zhenge ^a   Zhang, Shuirong ^a   Wang, Wenrong ^b   Hu, Ping ^a  

^a YANGTZE UNIVERSITY   (China)

^b Jingzhou Third People's Hospital   (China)

Author keywords

Drug repositioning; Ovarian neoplasms; Pyrvinium compounds; Wnt signaling pathway

Indexed keywords

BETA CATENIN; CISPLATIN; CYCLIN D; MYC PROTEIN; PACLITAXEL; PEPTIDES AND PROTEINS; PROTEIN BCL 9; PYRVINIUM EMBONATE; UNCLASSIFIED DRUG; WNT PROTEIN; ANTHELMINTIC AGENT; ANTINEOPLASTIC AGENT; LITHIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MOUSE; MTS ASSAY; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; XENOGRAFT; ANIMAL; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE; WNT SIGNALING PATHWAY;

ANIMALS; ANTHELMINTICS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; LITHIUM CHLORIDE; MICE, SCID; OVARIAN NEOPLASMS; PACLITAXEL; PYRVINIUM COMPOUNDS; WNT SIGNALING PATHWAY;

EID: 85010285212     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.901667     Document Type: Article

References (27)

1. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. Cancer J Clin, 2015; 65(1): 5-29
2. Agarwal R, Kaye SB: Ovarian cancer: Strategies for overcoming resistance to chemotherapy. Nat Rev Cancer, 2003; 3(7): 502-16
3. Bast RC Jr., Hennessy B, Mills GB: The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer, 2009; 9(6): 415-28
4. Su HY, Lai HC, Lin YW et al: Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer, 2010; 127(3): 555-67
5. Bodnar L, Stanczak A, Cierniak S et al: Wnt/βeta-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovarian Res, 2014; 7: 16
6. Thorne CA, Hanson AJ, Schneider J et al: Small-molecule inhibition of Wnt signaling through activation of casein kinase 1alpha. Nat Chem Biol, 2010; 6(11): 829-36
7. Xu W, Lacerda L, Debeb BG et al: The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer. PLoS One, 2013; 8(8): e71508
8. Deng L, Lei Y, Liu R et al: Pyrvinium targets autophagy addiction to promote cancer cell death. Cell Death Dis, 2013; 4: e614
9. Harada Y, Ishii I, Hatake K, Kasahara T: Pyrvinium pamoate inhibits proliferation of myeloma/erythroleukemia cells by suppressing mitochondrial respiratory complex I and STAT3. Cancer Lett, 2012; 319(1): 83-88
10. Yu DH, Macdonald J, Liu G et al: Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy. PLoS One, 2008; 3(12): e3951
11. Ishii I, Harada Y, Kasahara T: Reprofiling a classical anthelmintic, pyrvinium pamoate, as an anti-cancer drug targeting mitochondrial respiration. Front Oncol, 2012; 2: 137
12. Xiao M, Zhang L, Zhou Y et al: Pyrvinium selectively induces apoptosis of lymphoma cells through impairing mitochondrial functions and JAK2/STAT5. Biochem Biophys Res Commun, 2016; 469(3): 716-22
13. Veeman MT, Slusarski DC, Kaykas A et al: Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr Biol, 2003; 13(8): 680-85
14. Hua W, Christianson T, Rougeot C et al: SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. J Steroid Biochem Mol Biol, 1995; 55(3-4): 279-89
15. Han X, Du F, Jiang L et al: A2780 human ovarian cancer cells with acquired paclitaxel resistance display cancer stem cell properties. Oncol Lett, 2013; 6(5): 1295-98
16. Deng Z, Wang L, Hou H et al: Epigenetic regulation of IQGAP2 promotes ovarian cancer progression via activating Wnt/beta-catenin signaling. Int J Oncol, 2016; 48(1): 153-60
17. Arend RC, Londono-Joshi AI, Straughn JM Jr., Buchsbaum DJ: The Wnt/betacatenin pathway in ovarian cancer: A review. Gynecol Oncol, 2013; 131(3): 772-79
18. Kim S, Jho EH. The protein stability of Axin, a negative regulator of Wnt signaling, is regulated by Smad ubiquitination regulatory factor 2 (Smurf2). J Biol Chem, 2010; 285(47): 36420-26
19. Behrens BC, Hamilton TC, Masuda H et al: Characterization of a cisdiamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res, 1987; 47(2): 414-18
20. Barghout SH, Zepeda N, Xu Z et al: Elevated beta-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells. Biochem Biophys Res Commun, 2015; 468(1-2): 173-78
21. Boone JD, Arend RC, Johnston BE et al: Targeting the Wnt/beta-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974. Lab Invest, 2016; 96(2): 249-59
22. Arend RC, Londono-Joshi AI, Samant RS et al: Inhibition of Wnt/beta-catenin pathway by niclosamide: A therapeutic target for ovarian cancer. Gynecol Oncol, 2014; 134(1): 112-20
23. Xu L, Zhang L, Hu C et al: WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells. Int J Oncol, 2016; 48(3): 1175-86
24. Li B, Flaveny CA, Giambelli C et al: Repurposing the FDA-approved pinworm drug pyrvinium as a novel chemotherapeutic agent for intestinal polyposis. PLoS One, 2014; 9(7): e101969
25. Li B, Fei DL, Flaveny CA et al: Pyrvinium attenuates Hedgehog signaling downstream of Smoothened. Cancer Res, 2014; 74(17): 4811-21
26. Li H, Jiao S, Li X et al: Therapeutic effects of antibiotic drug tigecycline against cervical squamous cell carcinoma by inhibiting Wnt/beta-catenin signaling. Biochem Biophys Res Commun, 2015; 467(1): 14-20
27. Osada T, Chen M, Yang XY et al: Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res, 2011; 71(12): 4172-82